- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Tasigna
Synonyms :
Nilotinib, Nilotinibum
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
Dosage Forms & Strengths
capsule
150mg
200mg
chronic Myelogenous leukemia (CML)
It is used for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase Ph+ CML-CP:
300
mg
Orally
twice a day
Dosage Forms & Strengths
capsule
50mg
150mg
200mg
chronic Myelogenous leukemia (CML)
For > 1year children
230 mg per m2 orally 2x a day
and round to the nearest 50 mg dose
the Maximum dose given is 400 mg per dose
Dosing based on body surface area (BSA):
if BSA 0.32 m2: 50 mg orally 2x a day
if BSA 0.33-0.54 m2: 100 mg orally 2x a day
if BSA 0.55-0.76 m2: 150 mg orally 2x a day
if BSA 0.77-0.97 m2: 200 mg orally 2x a day
if BSA 0.98-1.19 m2: 250 mg orally 2x a day
if BSA 1.2-1.41 m2: 300 mg orally 2x a day
if BSA 1.42-1.63 m2: 350 mg orally 2x a day
if BSA 1.64 m2: 400 mg orally 2x a day
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval and toxicity of nilotinib
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval and toxicity of nilotinib
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval serious
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased level of afatinib by p-glycoprotein (mdr1) efflux transporter
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be a decreased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased level of bosutinib by p-glycoprotein (mdr1) efflux transporter
when both drugs are combined, there may be a decreased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be increased toxicity of nilotinib by qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
nilotinib: they may diminish the serum concentration of antacids
nilotinib: they may diminish the serum concentration of antacids
nilotinib: they may diminish the serum concentration of antacids
nilotinib: they may diminish the serum concentration of antacids
nilotinib: they may diminish the serum concentration of antacids
may enhance the QTc-prolonging effect of Nilotinib
may enhance the QTc-prolonging effect of Nilotinib
may enhance the QTc-prolonging effect of Nilotinib
may enhance the QTc-prolonging effect of Nilotinib
may enhance the QTc-prolonging effect of Nilotinib
may have an increased QTc-prolonging effect when combined with nilotinib
may have an increased QTc-prolonging effect when combined with nilotinib
may have an increased QTc-prolonging effect when combined with nilotinib
may have an increased QTc-prolonging effect when combined with nilotinib
may have an increased QTc-prolonging effect when combined with nilotinib
nilotinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
nilotinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
nilotinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
nilotinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
QTc interval is increased both by lenvatinib and nilotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nilotinib
nilotinib and gilteritinib, when used in combination, increase the QTc interval
may increase the QTc interval when combined
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased effect of alprazolam by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased level of nilotinib by increasing gastric ph
when both drugs are combined, there may be an increased effect of oxycodone by affecting hepatic enzyme cyp2d6 metabolism
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increased effect of paclitaxel by p-glycoprotein (mdr1) efflux transporter
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
when both drugs are combined, there may be a reduced metabolism of paclitaxel
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
the effect of nilotinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
osimertinib and nilotinib, when used simultaneously, increase the QTc interval
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may increase the QTc prolonging effect of QT-prolonging agents
when both drugs are combined, there may be an increased effect of alfentanil by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of aliskiren by p-glycoprotein (mdr1) efflux transporter
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it increases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
Adverse drug reactions:
Frequency defined
>10%
Arthralgia
Cough
Extremity pain
Asthenia
Rash
Headache
Nausea
Pruritus
Fatigue
Pyrexia
Diarrhea
Constipation
Vomiting
Muscle spasms
Myalgia
Abdominal pain
Bone pain
Back pain
Dyspnea
Nasopharyngitis
Peripheral edema
<10%
Dizziness
Insomnia
Hyperglycemia
Hyperkalemia
Hypomagnesemia
Neutropenia
Pancytopenia
Paresthesia
QT interval prolongation
HTN
Palpitations
QT interval prolongation
<1%
Aortic valve sclerosis
Abscess
Amnesia
Dehydration
Peripheral arterial occlusive disease
Tumor lysis syndrome
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Nilotinib is an anti-cancer drug helpful in treating certain blood cancer (CML-chronic myelogenous leukemia). It works by retarding or cessing the growth of cancerous cells.
The medicine is taken orally twice daily in the form of capsules.
Take plenty of water and fluids during nilotinib treatment.
Side effects of nilotinib are vomiting, nausea, headache, constipation, diarrhea, tiredness, irregular heartbeat. This drug also decreases bone marrow function.
Tell your physician if you develop any serious side effects.
Do not share your chemotherapeutic medications with others.
If you miss a dose, utilize it as soon as you think about it. And if it is near to the next dose, do not double the dose.
Nilotinib is not at all suitable for pregnant females as it harms the ingrowing foetus and causes birth defects.
Passage of chlorambucil in breast milk is still not known but is contraindicated during breast feeding.
Store the medication at room temperature in a moisture free space away from sunlight. It should not be held by children and pets.
